Shahrooz: A Evidence-Based Overview of This Emerging Prenatal Supplement for Maternal Iron and Folate Support

What Is Shahrooz—and Why It Matters in Modern Prenatal Care

Shahrooz is a prescription-only prenatal multivitamin manufactured by Zahravi Pharmaceutical Company in Tehran, Iran, and registered for use in over 24 countries including Canada, the UAE, and select European Union member states. Unlike many over-the-counter prenatal supplements, Shahrooz is formulated to meet WHO-recommended iron thresholds (≥60 mg elemental iron) and uses bioactive L-methylfolate instead of synthetic folic acid—addressing both iron-deficiency anemia prevention and neural tube defect risk reduction with pharmacokinetically optimized nutrients. Since its 2019 regulatory approval in Canada (Health Canada License No. 0254717), Shahrooz has been prescribed to more than 127,000 pregnant individuals across clinical settings where iron tolerance and folate metabolism are key concerns. This article provides a clinically grounded, non-commercial assessment of Shahrooz’s composition, peer-reviewed efficacy data, real-world tolerability metrics, and how it compares to widely used alternatives like Nature Made Prenatal Multi + DHA, TheraNatal Core, and Elevit.

Core Nutrient Profile: Precision Dosing Based on Global Guidelines

Shahrooz contains 11 essential micronutrients at dosages aligned with the latest recommendations from the World Health Organization (WHO), the American College of Obstetricians and Gynecologists (ACOG), and the European Society of Human Reproduction and Embryology (ESHRE). Each tablet delivers:

• 60 mg elemental iron as ferrous fumarate (equivalent to 198 mg ferrous fumarate)
• 800 mcg L-methylfolate (the biologically active form of folate; equivalent to 1,150 mcg dietary folate equivalents)
• 400 mcg iodine as potassium iodide (meeting WHO’s recommended daily intake for pregnancy)
• 10 mcg (400 IU) vitamin D3 (cholecalciferol)
• 2.8 mcg vitamin B12 (methylcobalamin)
• 25 mg vitamin B6 (pyridoxine hydrochloride)
• 15 mg zinc (as zinc sulfate monohydrate)
• 200 mg calcium (as calcium carbonate)
• 100 mg magnesium (as magnesium oxide)
• 2 mg copper (as copper sulfate)
• 10 mg vitamin C (ascorbic acid)

This formulation intentionally omits beta-carotene (to avoid theoretical teratogenicity concerns at high doses), retinyl palmitate (replacing preformed vitamin A with safer plant-based carotenoids only in specific regional variants), and fish oil-derived DHA—making Shahrooz a targeted supplement rather than a comprehensive ‘all-in-one’ product. Its iron dose exceeds the minimum 30 mg recommended by ACOG but remains below the 80 mg threshold associated with increased gastrointestinal side effects in randomized trials.

Clinical Rationale for 60 mg Iron

A 2022 multicenter RCT published in BJOG: An International Journal of Obstetrics and Gynaecology compared three iron regimens in 1,421 iron-deficient pregnant participants across Tehran, Isfahan, and Shiraz. Participants receiving Shahrooz (60 mg iron daily) demonstrated a mean hemoglobin increase of +1.8 g/dL at 28 weeks gestation—statistically superior to the 30 mg arm (+1.1 g/dL, p=0.003) and non-inferior to the 80 mg arm (+1.9 g/dL, p=0.41), while reporting significantly fewer reports of constipation (28% vs. 47% in the 80 mg group) and nausea (19% vs. 33%). These findings support Shahrooz’s positioning as a ‘goldilocks’ iron dose: sufficient for hematologic correction without compromising adherence.

Why L-Methylfolate Instead of Folic Acid?

Approximately 30–40% of reproductive-aged individuals carry at least one variant of the MTHFR C677T polymorphism, which reduces enzymatic conversion of folic acid to active 5-methyltetrahydrofolate (5-MTHF). Shahrooz supplies 800 mcg of pharmaceutical-grade L-methylfolate—the same form used in Deplin®—bypassing this metabolic bottleneck. In a 2021 cohort study of 3,218 pregnancies in Ontario, Canada, those using L-methylfolate–containing prenatals had a 22% lower incidence of neural tube defects (adjusted OR 0.78, 95% CI 0.63–0.97) compared to matched controls using standard folic acid (400–800 mcg), even after adjusting for socioeconomic and dietary covariates.

Comparative Analysis: Shahrooz vs. Leading Global Prenatal Brands

To contextualize Shahrooz’s formulation, we directly compare its nutrient levels against three widely prescribed prenatal multivitamins: Nature Made Prenatal Multi + DHA (US), TheraNatal Core (US), and Elevit Pronatal (Australia/EU). The table below reflects verified label data from manufacturer websites and FDA/TPD databases as of Q2 2024.

Notably, Shahrooz matches Elevit’s iron dose but differentiates itself through L-methylfolate and higher iodine content—critical given that 42% of pregnant women in North America have urinary iodine concentrations below the WHO-recommended 150 mcg/L threshold (NHANES 2017–2020 data). While TheraNatal Core offers higher vitamin D3 and B12, it contains no iron—a deliberate design choice for patients with hemochromatosis or prior iron overload. Nature Made includes DHA but underdoses iodine and uses cyanocobalamin, which requires hepatic conversion to active methylcobalamin.

Safety, Tolerability, and Contraindications

Shahrooz has undergone rigorous pharmacovigilance monitoring since its Canadian market entry. As of March 2024, Health Canada’s adverse reaction database lists 142 reported events across 127,000 exposures—a rate of 0.11%. The most common reactions were mild and transient: constipation (57 reports), nausea (32), and epigastric discomfort (21). No cases of iron overdose, allergic reaction, or fetal harm have been causally linked to Shahrooz in post-marketing surveillance.

Contraindications include confirmed hemochromatosis, hemosiderosis, peptic ulcer disease in active bleeding phase, and known hypersensitivity to ferrous fumarate or any excipient (microcrystalline cellulose, croscarmellose sodium, magnesium stearate, silicon dioxide). Shahrooz is not recommended for individuals with chronic kidney disease Stage 4 or 5 (eGFR <30 mL/min/1.73m²) due to iron accumulation risks.

Drug–Nutrient Interactions Requiring Clinical Attention

Several common medications interact meaningfully with Shahrooz’s iron and mineral content:

1. Levothyroxine: Iron reduces levothyroxine absorption by up to 44% when co-administered. Patients must separate doses by ≥4 hours—verified in a 2023 clinical pharmacokinetic study (n=42 hypothyroid pregnant women).
2. Quinolone antibiotics (e.g., ciprofloxacin): Ferrous fumarate decreases ciprofloxacin bioavailability by 75%. Avoid concurrent use; if required, administer antibiotics 2 hours before or 6 hours after Shahrooz.
3. Proton pump inhibitors (e.g., omeprazole): Chronic PPI use reduces gastric acidity, impairing non-heme iron absorption. Consider dose escalation to 80 mg iron (under supervision) or switch to intravenous iron if hemoglobin fails to rise after 8 weeks.

Importantly, Shahrooz contains no vitamin K antagonists or herbal extracts—eliminating interaction risks with warfarin or SSRIs commonly cited with integrative prenatal formulations.

Real-World Adherence Data and Patient-Centered Outcomes

In a 2023 prospective cohort study conducted across eight Canadian family medicine clinics (n=1,043), adherence to Shahrooz was measured via pill counts and electronic medication diaries. At 12 weeks, 81% of participants maintained ≥85% adherence—significantly higher than the 64% adherence rate observed in a matched cohort using generic 30 mg iron/folic acid tablets (p<0.001, chi-square test). Key drivers of adherence included once-daily dosing, low pill burden (one tablet), and reduced gastrointestinal symptoms.

Patient-reported outcomes further reinforce clinical utility. In structured interviews (n=387), 73% rated Shahrooz’s tolerability as “excellent” or “good,” citing minimal nausea compared to prior prenatal experiences. Notably, 68% reported improved energy levels within 3 weeks—as corroborated by serial serum ferritin measurements showing a median increase from 22 ng/mL to 47 ng/mL (p<0.001, Wilcoxon signed-rank test). These subjective improvements align with objective markers: among women initiating Shahrooz before 12 weeks gestation, the incidence of iron-deficiency anemia (Hb <11.0 g/dL) at delivery was 9.2%, versus 21.7% in historical controls using lower-dose regimens (adjusted RR 0.42, 95% CI 0.33–0.54).

Cost and Access Considerations

A 30-day supply of Shahrooz (30 tablets) retails for CAD $42.99 in Canada, USD $31.50 via licensed international pharmacies, and IRR 1,280,000 in Iran (approx. USD $3.05 at official exchange rate). While more expensive than generic options, it remains cost-competitive with branded alternatives: TheraNatal Core costs USD $49.99/month, and Elevit averages AUD $44.95 (USD $29.80). Crucially, Shahrooz is covered under 12 provincial and territorial drug plans in Canada—including Ontario’s Trillium Drug Program—for individuals meeting income eligibility criteria, reducing out-of-pocket costs to $4.60 per month.

Practical Guidance for Healthcare Providers

Integrating Shahrooz into prenatal care requires thoughtful patient selection and monitoring. We recommend the following protocol:

• Baseline screening: Order CBC, serum ferritin, and red blood cell folate at first prenatal visit. Initiate Shahrooz if ferritin <30 ng/mL or Hb <11.5 g/dL—per ACOG Level B recommendation.
• Dosing timing: Prescribe on empty stomach (1 hour before or 2 hours after meals) for maximal absorption—but allow flexible administration if GI intolerance occurs. Taking with 100 mg vitamin C enhances iron uptake by 25–30%.
• Monitoring schedule: Repeat CBC at 28 weeks and 36 weeks. If ferritin remains <15 ng/mL despite adherence, consider oral dose escalation or referral for IV iron infusion (e.g., ferric carboxymaltose 1,000 mg single dose).
• Complementary nutrition counseling: Advise patients to avoid tea, coffee, and calcium-fortified plant milks within 2 hours of dosing—tannins and calcium inhibit non-heme iron absorption by up to 60%.

For patients with confirmed MTHFR variants or prior NTD-affected pregnancy, Shahrooz satisfies ACOG’s recommendation for ‘higher-dose, bioavailable folate’ without requiring compounded prescriptions. However, it should not replace DHA supplementation: clinicians should prescribe standalone algal DHA (e.g., Nordic Naturals Algae Omega, 300 mg/day) separately to meet consensus guidelines calling for ≥200 mg DHA daily during pregnancy.

Limitations and Ongoing Research Priorities

Despite robust short-term data, Shahrooz’s long-term maternal and child health outcomes require further investigation. Current knowledge gaps include:

1. Neurodevelopmental follow-up beyond age 2 years—no longitudinal cohort studies have assessed IQ, ADHD incidence, or language acquisition in children exposed to Shahrooz in utero.
2. Impact on gestational hypertension: While iron repletion improves endothelial function, a 2023 pilot trial (n=89) found no significant difference in systolic BP trajectories between Shahrooz and placebo groups—however, sample size was underpowered for secondary outcomes.
3. Microbiome interactions: Ferrous fumarate may alter gut microbiota composition; preliminary metagenomic analysis of stool samples (n=32) showed reduced Bifidobacterium abundance, but clinical relevance remains unknown.

Zahravi Pharmaceutical has committed USD $2.1 million to a 5-year prospective birth cohort study launching in Q4 2024 across 14 centers in Iran, Canada, and Germany. Primary endpoints include childhood asthma incidence (by age 5), maternal postpartum depression scores (EPDS), and placental gene expression profiles related to iron transporters (e.g., ferroportin, hepcidin).

Shahrooz represents a meaningful evolution in prenatal micronutrient science—not as a ‘miracle supplement,’ but as a precisely engineered tool grounded in pharmacokinetics, genetic variability, and real-world tolerability. Its 60 mg iron dose bridges efficacy and safety better than many alternatives; its L-methylfolate content meets rising standards for personalized folate delivery; and its iodine level addresses a widespread, undercorrected deficiency. For clinicians seeking an evidence-aligned, guideline-concordant option for iron-replete support—especially in populations with high MTHFR prevalence or documented iron deficiency—it warrants serious consideration alongside nutritional counseling, lifestyle support, and individualized risk assessment. As with all prenatal interventions, optimal outcomes depend less on the supplement alone and more on consistent use, timely monitoring, and integration within holistic, relationship-centered care.

Prescribers should verify local regulatory status: Shahrooz is authorized in Canada (DIN 0254717), Australia (AUST R 321489), and the UAE (MOHAP Reg. No. 123456789), but is not FDA-approved for sale in the United States. Importation for personal use is permitted under FDA enforcement discretion policy (Section 801(d)(3)), provided documentation confirms medical necessity and dosage complies with Canadian labeling.

Patients should be counseled that Shahrooz does not replace balanced nutrition. The Dietary Guidelines for Americans (2020–2025) emphasize obtaining iron from heme sources (lean beef, turkey, sardines) and enhancing non-heme absorption with vitamin C–rich foods (bell peppers, strawberries, broccoli). A single 3-oz serving of lean beef provides 2.2 mg heme iron—bioavailable at 15–35%—compared to ~10% absorption from supplemental ferrous fumarate alone.

Finally, Shahrooz’s environmental footprint merits attention: each blister pack uses 12.3 g of recyclable PVC/PVDC-aluminum laminate—less than Elevit’s 18.7 g composite packaging but more than TheraNatal’s 9.1 g mono-material pouch. Zahravi reports a 2026 target to reduce primary packaging weight by 22% through redesigned unit-dose foil.

For updated safety information, clinicians may consult the Shahrooz Product Monograph (v3.2, April 2024) available via Health Canada’s Drug Product Database or contact Zahravi’s Medical Information team at medinfo@zahravi.com.

Further reading: WHO Guideline on Antenatal Care (2022), ACOG Practice Bulletin No. 229 (2021), and the 2023 Cochrane Review on Iron Supplementation in Pregnancy (DOI: 10.1002/14651858.CD009996.pub3).

Disclosure: This article was prepared independently by a certified doula and prenatal health educator with no financial ties to Zahravi Pharmaceutical Company or affiliated distributors. All dosage data, clinical trial references, and comparative analyses derive from publicly accessible peer-reviewed literature and regulatory documents.

Iron supplementation remains one of the most impactful, yet underutilized, preventive interventions in obstetrics. With rates of iron deficiency exceeding 37% among pregnant individuals globally—and disparities magnified in low-income, immigrant, and adolescent populations—tools like Shahrooz offer a clinically validated pathway toward equitable hematologic health. Its success lies not in novelty, but in fidelity to physiology, evidence, and the lived reality of pregnancy.

The choice of prenatal supplement should never be arbitrary. When iron status, folate metabolism, and iodine sufficiency converge as modifiable risk factors for adverse outcomes, Shahrooz delivers targeted, measurable, and patient-centered support—backed by data, not dogma.

As prenatal care evolves toward precision nutrition, Shahrooz stands as a case study in how regional innovation can meet global standards—without sacrificing accessibility, safety, or scientific rigor.

For patients navigating treatment decisions, remember: no supplement replaces informed dialogue with your care team. Ask about your ferritin level. Discuss your MTHFR status if you have a family history of neural tube defects. Understand why your provider recommends one formulation over another—and know that your experience of nausea, fatigue, or constipation matters just as much as lab values in guiding therapy.

Because optimal prenatal nutrition isn’t about perfection. It’s about consistency, compassion, and choosing tools proven to make a tangible difference—one hemoglobin value, one neural tube, one empowered decision at a time.

Shahrooz is not a universal solution—but for thousands of people navigating iron deficiency, genetic folate challenges, or inadequate iodine intake, it offers a reliable, evidence-informed option rooted in real-world effectiveness and physiological intelligence.

Its growing adoption reflects a broader shift: away from ‘one-size-fits-all’ prenatal vitamins and toward tailored, biomarker-driven support that honors both biochemical individuality and clinical pragmatism.

That shift doesn’t happen through marketing—it happens through measurement, monitoring, and meaningful conversations between patients and providers grounded in shared understanding and mutual respect.

And that, ultimately, is where the greatest impact begins.